Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT06674109
PHASE4

SAVE-Care (Sodium Glucose Cotransporter-2 Inhibitors [SGLT2i] As Novel Gout Care) Trial

Sponsor: Massachusetts General Hospital

View on ClinicalTrials.gov

Summary

SAVE-Care (Sodium Glucose Cotransporter-2 inhibitors \[SGLT2i\] As Novel Gout Care) Trial is a double-blind randomized placebo-controlled trial (RCT) designed to assess the effect of empagliflozin on serum urate \[SU\] levels of gout patients, as well as levels of highly-sensitivity C-reactive protein \[hsCRP\] and interleukin 6 \[IL-6\], and estimate gout flares over 3 months, in order to develop a full-scale RCT of clinical endpoints to directly inform gout care guidelines.

Official title: SAVE-Care (SGLT2i As Novel Gout Care) Trial

Key Details

Gender

All

Age Range

18 Years - 80 Years

Study Type

INTERVENTIONAL

Enrollment

60

Start Date

2026-04-30

Completion Date

2028-02-28

Last Updated

2026-03-30

Healthy Volunteers

No

Interventions

DRUG

Empagliflozin 10 mg

For the empagliflozin arm, participants will take 10 mg daily.

DRUG

Placebo

Participants in the placebo arm will take a placebo daily.